Vivani Medical logo

Vivani MedicalNASDAQ: VANI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 November 2014

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$76.25 M
-63%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-67%vs. 3y high
72%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 22:31:16 GMT
$1.38+$0.04(+2.99%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

VANI Latest News

VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024
InvestorPlace13 May 2024 Sentiment: NEGATIVE

Vivani Medical (NASDAQ: VANI) has recently released their first quarter 2024 results, showing earnings per share of -12 cents.

Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
MarketBeat06 March 2024 Sentiment: POSITIVE

The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks continue to surge higher. Shares of Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO are already up 20% year-to-date (YTD).

Why Is Vivani Medical (VANI) Stock Up 300% Today?
InvestorPlace28 February 2024 Sentiment: POSITIVE

Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ: VANI ) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company's weight-loss solution, which offered compelling results compared to mainline weight-loss therapeutics.

What type of business is Vivani Medical?

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.

What sector is Vivani Medical in?

Vivani Medical is in the Healthcare sector

What industry is Vivani Medical in?

Vivani Medical is in the Biotechnology industry

What country is Vivani Medical from?

Vivani Medical is headquartered in United States

When did Vivani Medical go public?

Vivani Medical initial public offering (IPO) was on 19 November 2014

What is Vivani Medical website?

https://www.vivani.com

Is Vivani Medical in the S&P 500?

No, Vivani Medical is not included in the S&P 500 index

Is Vivani Medical in the NASDAQ 100?

No, Vivani Medical is not included in the NASDAQ 100 index

Is Vivani Medical in the Dow Jones?

No, Vivani Medical is not included in the Dow Jones index

When was Vivani Medical the previous earnings report?

No data

When does Vivani Medical earnings report?

The next expected earnings date for Vivani Medical is 13 November 2024